Dr. Steven F. Polyak, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 143
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
IA license 38753 · FL license ME91577 -
Internal Medicine Physician
IA license 38753
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 143
- Services billed
- 279
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 40 | 40 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 25 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 14 | 11 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | 14 |
| Biopsy of large bowel using a flexible endoscope | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rinvoq (upadacitinib) | 35 |
| Azathioprine Other prescribers in Iowa City, IA | 21 |
| Ciprofloxacin Hcl Other prescribers in Iowa City, IA | 14 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Iowa City, IA | 12 |
| Omeprazole Other prescribers in Iowa City, IA | 12 |
| Acetaminophen-Codeine (acetaminophen with codeine) Other prescribers in Iowa City, IA | 11 |
| Sulfasalazine Other prescribers in Iowa City, IA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $201,781 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Sanofi US Services Inc. · Active, not recruiting · NCT06975722 - A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Sanofi US Services Inc. · Recruiting · NCT06958536 - TAK-279 CD/UC Ph2 OLE
Takeda Pharmaceuticals U.S.A., Inc. - A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative…
Teva Pharmaceuticals USA, Inc. - A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to …
Takeda Pharmaceuticals U.S.A., Inc. - A phase 1B randomized doubleblind placebocontrolled multicenter study to evaluate the efficacy safety and pharmacokinetics of oral PF07054894 in adult participants aged 1875 years with moderate to severe ulcerative co…
Pfizer Inc. - A phase 4 study evaluating real-world use of cdpath?, a crohn's disease risk prediction tool
Takeda Pharmaceuticals U.S.A., Inc. - A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE …
Teva Pharmaceuticals USA, Inc. - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.